Authors: Andringa, G van Oosten, RV Unger, W Hafmans, TGM Veening, J Stoof, JC Cools, AR

Citation: G. Andringa et al., Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra, EUR J NEURO, 12(8), 2000, pp. 3033-3043

Authors: Andringa, G Stoof, JC Cools, AR

Citation: G. Andringa et al., Sub-chronic administration of the dopamine D-1 antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia, PSYCHOPHAR, 146(3), 1999, pp. 328-334

Authors: Andringa, G Vermeulen, RJ Drukarch, B Renier, WO Stoof, JC Cools, AR

Citation: G. Andringa et al., The validity of the pretreated, unilaterally MPTP-treated monkey as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF81297, BEHAV PHARM, 10(2), 1999, pp. 163-173

Authors: Andringa, G Lubbers, L Drukarch, B Stoof, JC Cools, AR

Citation: G. Andringa et al., The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF82958, BEHAV PHARM, 10(2), 1999, pp. 175-182

Authors: Andringa, G Drukarch, B Leysen, JE Cools, AR Stoof, JC

Citation: G. Andringa et al., The alleged dopamine D-1 receptor agonist SKF 83959 is a dopamine D-1 receptor antagonist in primate cells and interacts with other receptors, EUR J PHARM, 364(1), 1999, pp. 33-41